Description

4-(3',4'-Difluoroanilino)-6-Hydroxy-7-Methoxyquinazoline is a high-purity, advanced pharmaceutical intermediate belonging to the quinazoline class of compounds. This compound is of significant commercial interest for its role as a key building block in the synthesis of targeted therapeutic agents, particularly tyrosine kinase inhibitors. It is primarily required by research institutions and pharmaceutical manufacturers engaged in the development and production of novel oncology treatments. The precise molecular architecture of this intermediate enables the creation of potent and selective drug candidates.

Application

• Pharmaceutical Intermediate: A critical precursor in the multi-step synthesis of novel small-molecule drugs, especially tyrosine kinase inhibitors (TKIs) targeting specific cancer pathways.
• Oncology Drug Research: Serves as a core scaffold in medicinal chemistry programs for developing anti-cancer agents, leveraging its quinazoline structure for receptor binding.
• Chemical Reference Standard: Used as a high-purity analytical standard in quality control laboratories for method development, validation, and impurity profiling of active pharmaceutical ingredients (APIs).
• Process Development & Scale-Up: Employed in process chemistry for optimizing synthetic routes, improving yield, and ensuring reproducibility during the transition from lab-scale to commercial manufacturing.
• Academic & Contract Research: Utilized in university and CRO (Contract Research Organization) settings for fundamental research on kinase inhibition mechanisms and structure-activity relationships (SAR).

Basic Information

Product Name	4-(3',4'-Difluoroanilino)-6-Hydroxy-7-Methoxyquinazoline
CAS No.	184475-78-3
Molecular Formula	C₁₅H₁₁F₂N₃O₂
Molecular Weight	303.27 g/mol
Synonyms	4-[(3,4-Difluorophenyl)amino]-6-hydroxy-7-methoxyquinazoline; 6-Hydroxy-7-methoxy-4-(3,4-difluoroanilino)quinazoline; 4-(3,4-Difluoroanilino)-6-hydroxy-7-methoxyquinazoline; 184475-78-3; UNII-9J6K9N9220; 9J6K9N9220; BDBM50111071; AKOS005714947; A-841720.1; SCHEMBL11806227
EINECS	Contact for details

Quality Control

Our 4-(3',4'-Difluoroanilino)-6-Hydroxy-7-Methoxyquinazoline is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC for purity and identity confirmation, to ensure it meets the stringent requirements for pharmaceutical R&D and manufacturing. Certificates of Analysis (COA) with detailed chromatographic data are provided for every shipment, supporting regulatory filings and internal quality assurance protocols.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). The product is light-sensitive and should be handled under appropriate conditions to maintain stability and potency.

Specification

Item	Specification
Appearance	Off-white to light yellow powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Loss on Drying	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.